SavedAdd your journal

Journals / Clinical and Experimental Health Sciences / 2019 / Cilt: 9 - Sayı: 1

Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?

Selami Aykut TEMİZ
Arzu ATASEVEN
İlkay OZER
Recep DURSUN
Siddika FİNDİK
Pages
91–93
Publication Date
2019-03-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically
📊
Key Findings & Data:Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically
💡
Conclusion & Impact:Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Urticarial vasculitis · methotrexate · omalizumab

Abstract

Objective: Urticarial vasculitis is a chronic clinicopathologic entity characterized by clinically characterized urticarial rash, histopathologically

🔖

Cite This Article

TEMİZ, S. A., ATASEVEN, A., OZER, İ., DURSUN, R., FİNDİK, S. (2019). Refractory Urticarial Vasculitis Responsive to Methotrexate: Could It Be a New Treatment Option?. Clinical and Experimental Health Sciences, Cilt: 9 - Sayı: 1, 91–93. https://ajindex.com/articles/481685

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract 2018;6(4):1162-70
  2. Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ. Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology (Oxford) 2018; 57(8):1400- 07
  3. Kavala M, Türkoğlu Z, Özlü E. Metotreksat ve dermatolojide klinik kullanımları. Med Med J 2014; 29:104-110
  4. Sunderkötter C, De Groot K. Therapie von Vaskulitiden und Vaskulopathien. Der Hautarzt 2008; 59:382
  5. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003; 48:311-40
  6. Polat AK, Belli AA, Karakus V, Dere Y. Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome. An Bras Dermatol 2017; 92:59-61
  7. Black AK. Urticarial vasculitis. Clinics in Dermatology 1999; 17:565-69
  8. Katsambas A, Riga P. Purpura and vasculitis: unapproved treatments. Clin Dermatol 2002; 20:626-33
  9. Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009; 123:1226-36. [10] 1Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1-18
  10. Thomas-Golbanov C, Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10:1279-89
  11. Stack PS. Methotrexate for urticarial vasculitis. Ann Allergy 1994; 72:36-38
  12. Perez A, Woods A, Grattan CEH. Methotrexate: a useful steroidsparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191-94
  13. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14-21
  14. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology 2014; 10:1519-30.